NCT02115321View on ClinicalTrials.gov

Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 9, 2014

Primary Completion Date

March 5, 2015

Study Completion Date

June 16, 2015

Conditions
Chronic Hepatitis C
Interventions
DRUG

Grazoprevir

GZR was supplied as two 25 mg tablets in the Part A CP-B arm, or as either one GZR 100 mg tablet or one fixed-dose combination (FDC) tablet containing GZR 100 mg + EBR 50 mg in a single tablet (MK-5172A) in the Part A NC arm. GZR was taken q.d. by mouth.

DRUG

Elbasvir

EBR was supplied as 50 mg tablets and was taken q.d. by mouth.

DRUG

MK-5172A

MK-5172A FDC tablet containing GZR 100 mg + EBR 50 mg taken q.d. by mouth.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02115321 - Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059) | Biotech Hunter | Biotech Hunter